New chief executive for AiCuris

pharmafile | January 22, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AiCuris, Holger Zimmermann, Rübsamen-Schaeff 

Founded in 2006 as a spin-off from Bayer, AiCuris has found a new chief executive as Helga Rübsamen-Schaeff steps aside to assume a board chair role.

After nine years at the helm of the German, Wuppertal-based biotech company – Rübsamen-Schaeff (pictured) will transition from her function as chief executive to chair of the board as of March.

Her successor will be the current chief scientific officer Dr Holger Zimmermann, who has been working together with Rübsamen-Schaeff in the development of innovative and resistance-breaking drugs against infectious diseases since the company’s foundation.

Advertisement

“During the past 9 years, Prof. Rübsamen- Schaeff transformed AiCuris from a spin-off into a globally renowned company. In 2012, under her leadership, AiCuris achieved one of the largest license agreements to-date in the European biotech industry. I am therefore very pleased that we will continue to profit from her extensive expertise as she assumes her role of chair of the board following the hand-over of operative business,” Zimmermann says.

Rübsamen-Schaeff adds she is delighted that AiCuris will “remain in Dr Zimmermann’s capable hands and will continue to support the company in the future – with an emphasis upon strategic advice and business development projects.”

Related Content

MSD’s antiviral drug hits endpoint targets in Phase III trials

MSD, known as Merck in the US, released news of the successful meeting of its …

Merck image

Merck enters €110m virus alliance

Merck has gained access to AiCuris’ portfolio of investigational medicines targeting human cytomegalovirus (HCMV) via …

The Gateway to Local Adoption Series

Latest content